BioHarvest Sciences (NASDAQ:BHST) Releases Earnings Results, Misses Estimates By $0.05 EPS

BioHarvest Sciences (NASDAQ:BHST) announced its quarterly earnings data on Monday. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.05), Zacks reports. The business had revenue of $7.17 million for the quarter, compared to the consensus estimate of $7.24 million.

BioHarvest Sciences Stock Up 4.8 %

Shares of BHST stock traded up $0.30 during trading hours on Tuesday, reaching $6.49. The company had a trading volume of 5,224 shares, compared to its average volume of 8,004. The stock has a market capitalization of $106.60 million, a P/E ratio of -5.20 and a beta of 2.27. The company’s fifty day simple moving average is $5.66. BioHarvest Sciences has a twelve month low of $6.15 and a twelve month high of $7.38.

Analysts Set New Price Targets

BHST has been the topic of a number of research reports. HC Wainwright began coverage on shares of BioHarvest Sciences in a research note on Friday, December 6th. They issued a “buy” rating and a $14.00 price objective on the stock. Maxim Group started coverage on shares of BioHarvest Sciences in a report on Wednesday, December 18th. They issued a “buy” rating and a $12.00 price target on the stock.

About BioHarvest Sciences

BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications.